The Variant Has No Approved Treatment, Which Makes (NYSE: NNVC) Worth Reading About

Most clinical programs follow a predictable order.

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored The Variant Has No Approved Treatment, Which Makes (NYSE: NNVC) Worth Reading About *Click Here To Get Our Alerts Faster Via SMS* August 21st Greetings Readers, Most clinical programs follow a predictable order. Approval first, shipping second. NanoViricides, Inc. (NYSE American: NNVC) ran that sequence in reverse. On August 10th, 2026, the company announced that ACOREP, the regulatory agency of the Democratic Republic of Congo, had cleared a Phase II clinical trial of NV-387 Oral Gum-mies as a treatment for Bund-i-bugyo E-bola-vi-rus and other E-bola strains. Tucked into the same release was a detail most skimmed past: the drug product was already in the DRC. The backdrop is severe. The company cited 4,141 confirmed cases and 1,889 confirmed deaths as of August 6th, 2026, then 4,945 confirmed cases and 2,325 deaths as of August 14th, with 101 new cases logged in a single 24-hour window and spread across six provinces. The crude fatality rate sits near 46%. NV-387 does not work the way most antivirals do. It is engineered to mimic heparan sulfate proteoglycan, a host cell surface feature the company states over 90% to 95% of human pathogenic vi-rus-es require in order to infect cells. The compound targets the doorway rather than the intruder, which is the basis for its broad-spectrum design. Format matters as much as chemistry. NV-387 is delivered as an oral gummy that dissolves in the mouth without water. That contrasts with the two approved E-bola antibody drugs, both given by intravenous infusion and cleared only for the Zaire species. The company states there is no approved treatment for the Bund-i-bugyo variant driving this outbreak. On August 18th, 2026, the company reported staff training underway, while Professor Patrick Katoto, Co-Director and Co-Founder of the Centre for Tropical Diseases and Global Health ("CTDGH"), and Associate Professor of Medicine, Epidemiology and Global Health at the Catholic University of Bukavu, Bukavu, DRC., was named to lead the trial, with first patient dosing expected within a few weeks absent outbreak delays. Om Sai Clinical Research Private Limited of India is the contract research organization. A Fireside Chat And A Quiet Designation Rewind seven weeks. On June 29th, 2026, Dr. Anil R. Diwan, founder and president, sat for a recorded fireside chat. He walked through how NV-387 is designed to work alongside vac.cines rather than compete with them, and how it departs from conventional antivirals. The same week carried harder news. The U.S. FDA granted Rare Pediatric Disease Drug designation for NV-387 as a treatment for measles, which opens the door to a Priority Review Voucher should the drug later w-i-n approval. Diwan framed it in commercial terms, saying the designation and voucher “make a strong business case for development of NV-387 as a drug for the treatment of Measles.” The company noted a separate voucher changed hands for $195Mn earlier this year. NV-387 had already received Orphan Drug designation for measles. The Shift: Four Steps In Six Weeks What followed was compressed. On July 8th, 2026, Noble Capital Markets initiated coverage with an Outperform rating and a $6.00 price target, authored by analyst Robert LeBoyer. On July 24th, it priced a registered direct offering of approximately $3.8Mn covering 2,516,339 shares plus warrants exercisable at $1.75, with D. Boral Capital LLC as placement agent. Four days later it confirmed financing was complete to support the anticipated E-bola trial. Designation, coverage, capital, clearance. About NanoViricides, Inc. (NYSE American: NNVC) NanoViricides is a a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. It owns its multi-kilogram-scale cGMP-capable manufacturing facility outright with no mortgage, producing both drug substance and drug product in house. Management states the plant can supply every program through human trials. The underlying platform is licensed on an exclusive, worldwide basis from TheraCour Pharma, Inc., founded by Dr. Anil R. Diwan. Rather than building around a single asset, the model applies one chemistry to many vi-rus-es. NV-387 addresses E-bola, m-pox and sm-all-pox, measles, and a planned respiratory basket covering RSV, influenza and cor-ona-vi-rus-es. NV-HHV-1 targets shingles. Biological testing runs through academic, private and federal laboratories, which limits internal spending. More Sources: NNVC Website. We're Tracking 7 Key Potential Catalysts Backing (NYSE American: NNVC) #1. Phase II Clearance Landed Inside An Active Out-break. Few clinical-stage developers get a green light while the target disease is still spreading, and NNVC now holds that clearance in DR Congo. #2. Drug Product Reached The Country Before The Approval Did. Shipping and site logistics normally add months to an African trial start, and NNVC handled that step before clearance arrived. #3. An Oral Gum-my Sidesteps Infusion Infrastructure Entirely. Competing E-bola treatments call for intravenous administration, while the format behind NNVC dissolves in the mouth without water. #4. Public Float Sits Below 22Mn Shares. The reported float is approximately 21.08Mn shares, which makes NNVC a low float idea where the potential for heightened volatility may be significant. #5. Two FDA Designations Open A Voucher Pathway In Measles. Orphan Drug and Rare Pediatric Disease Drug status put NNVC on a path where a voucher could be issued upon a future approval, and one such voucher sold for $195Mn this year. #6. Published Coverage Carries A $6.00 Target Price. Noble Capital Markets reiterated in August with a continued Outperform rating, giving NNVC a documented third-party reference point. #7. One Compound Feeds Four Separate Programs. E-bola, m-pox, measles and a planned respiratory basket all draw on the same molecule, so NNVC can generate several readouts from one chemistry. Closing Thoughts NanoViricides, Inc. (Nasdaq: NNVC) is not a finished story. NV-387 remains experimental, Phase II has not dosed its first patient, and clearance to run a clinical trial is a different matter from drug approval. What has changed is the setting. A small Connecticut developer with its own plant and a float under 22Mn shares now has regulatory clearance, a trial lead, a contract research organization, and product already positioned inside what the company calls the largest recorded E-bola out-break, against a variant with no approved treatment. Readers who track how narratives form before they are widely recognized may want to keep NNVC on the radar and review the company's releases directly. We're initiating coverage on NanoViricides, Inc. (Nasdaq: NNVC). Be on the lookout for updates coming out soon. Talk shortly. Sincerely, Kai Parker StockWireNews (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)

SWN Media | 4808 NW 2nd Ave Unit #388 | Boca Raton, FL 33431 US Unsubscribe | Constant Contact Data Notice